Prediction of Human Pharmacokinetics of Ulixertinib, a Novel ERK1/2 Inhibitor from Mice, Rats, and Dogs Pharmacokinetics

ConclusionsThe derived pharmacokinetic parameters (AUC andCmax at 600  mg dose) and simulated plasma concentration–time profiles of ulixertinib in humans were predicted with good confidence by allometric approach.
Source: European Journal of Drug Metabolism and Pharmacokinetics - Category: Drugs & Pharmacology Source Type: research